Endo Pharma in withdrawal: FDA requests opioid drug’s removal from the market
The FDA's move to request Endo Pharmaceuticals to remove its opioid drug Opana ER (oxymorphone hydrochloride) from the market is a first for the regulator.
FTC sues Endo Pharmaceuticals for paying off generic drugmakers – and delaying market entry
The Federal Trade Commission has sued Endo Pharmaceuticals and several other drugmakers, saying they've entered "pay-for-delay" deals that postpone generic versions of its drugs to hit the market.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Endo Pharmaceuticals’ ads bring awareness to penile curvature
Endo Pharmaceuticals' "Ask About the Curve" brings awareness to Peyronie's disease, which causes curvature of the penis.
How to solve the puzzle of end-to-end care? Just ask Endo Health Solutions
They say knowing is half the battle. Recognizing these three mantras was the first step that helped Endo Pharmaceuticals (NASDAQ:ENDP) transform itself from a pharmaceuticals company to Endo Health Solutions, a provider of drugs, devices and tech solutions that address the pain and urology market segments. Julie McHugh, the chief operating officer of Endo, mentioned […]
Drug shortage risk for Endo Pharmaceuticals after factory shut down
Endo Pharmaceuticals (NASDAQ:ENDP) faces a drug shortage risk for some of its opiates, such as Percocet, as Novartis Consumer Group sorts out a mix-up that could cause extended release opiates for Endo Pharmaceuticals to be bottled together with over-the-counter pain reliever Excedrin and stimulant NoDoz. The factory shutdown, though temporary, could cause a shortage for […]
Chronic pain treatment from BDSI licensed to Endo Pharma in $180M deal
The investigational chronic pain treatment from BioDelivery Sciences International (NASDAQ:BDSI) that failed in a late-stage clinical trial now has a partner and a plan that salvages the drug program and infuses the biopharmaceutical company with cash at a critical time. Endo Pharmaceuticals (NASDAQ:ENDP) has licensed pain treament candidate BEMA Buprenorphine in a deal that pays […]
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Endo Pharmaceuticals ends development of drug for growth hormone condition
Endo Pharmaceuticals (NASDAQ:ENDP) has ended its developments of an octreotide implant to treat a disorder in which the body produces too much growth hormone following a review of its research and development priorities, according to a filing with the U.S. Securities and Exchange Commission. The move was prompted in part by a request by the […]
Endo Pharmaceuticals gets green light for generic version of Plendil
Endo Pharmaceuticals (NASDAQ: ENDP) has received approval from the Food and Drug Administration for its drug Felodipine extended-release tablets, a generic version of AstraZeneca‘s (NYSE: AZN) drug, Plendil. The cardiovascular drug tallied $196 million in sales for AstraZeneca for the first nine months of 2011. The total sales for Felodipine in the U.S. for the […]
Endo acquires pelvic care firm American Medical Systems for $2.9B
Updated: 11:06 a.m. A company that began life in the pharmaceutical sector is venturing forth into devices in its quest to become more of a diversified healthcare company. Chadds Ford, Pennsylvania-based Endo Pharmaceuticals (NASDAQ: ENDP) announced today that the company is buying Minnetonka-based American Medical Systems (NASDAQ:AMMD), a manufacturer of new innovative medical devices focusing […]
ProNAi Therapeutics slices genes to treat cancer (Morning Read)
ProNAi Therapeutics in Kalamazoo, Michigan, says it's started to treat cancer patients with its first experimental DNA interference drug, which is made to silence the disease at the DNA level, according to Xconomy Detroit.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.